logo

For the Inventor, By the Inventor

South San Francisco, CA, United States of America

Cor Therapeutics, Inc.


USPTO Granted Patents = 92


Trademarks = 1

Forward Citations = 914

Loading Chart...
Loading Chart...

41 inventors (with patents filed for the assignee):

goldMedal Robert M Scarborough (59 out of 153 patents)

silverMedal David Lawrence Wolf (31 out of 33 patents)

bronzeMedal Bing-Yan Zhu (20 out of 79 patents)

4.  Israel F Charo (20 out of 23 patents)

5.  Uma Sinha (10 out of 32 patents)

6.  Charles K Marlowe (9 out of 22 patents)

7.  Neill A Giese (6 out of 11 patents)

8.  David R Phillips (6 out of 28 patents)

9.  Johan Sundelin (6 out of 8 patents)

10.  Shaun R Coughlin (5 out of 21 patents)

11.  Alan M Laibelman (5 out of 6 patents)

12.  Nathalie Lokker (5 out of 5 patents)

13.  Robert S King (4 out of 8 patents)

14.  Larry J Fretto (4 out of 7 patents)

15.  Ting Su (3 out of 9 patents)


Core Competencies:
Factor Xa
Thrombin Receptor
Platelet Aggregation
Inhibitors
Benzamides
Ketoheterocyclic
Integrin
C140 Receptor
Antithrombosis
Glycosylation
Nucleic Acids
Pharmaceuticals

92 patents:

1. 6399627 - Inhibitors of factor Xa (2002-06-04),
2. 6376515 - Benzamides and related inhibitors of factor Xa (2002-04-23),
3. 6369080 - Selective factor Xa inhibitors (2002-04-09),
4. 6369063 - Selective factor Xa inhibitors (2002-04-09),
5. 6333321 - Selective factor Xa inhibitors (2001-12-25),
6. 6297026 - Nucleic acids encoding the C140 receptor (2001-10-02),
7. 6262047 - Selective factor Xa inhibitors (2001-07-17),
8. 6245743 - Inhibitors of factor Xa (2001-06-12),
9. 6228854 - Selective factor Xa inhibitors (2001-05-08),
10. 6218382 - Selective factor Xa inhibitors (2001-04-17),
11. 6211183 - Selective factor Xa inhibitors (2001-04-03),
12. 6211154 - Ketoheterocyclic inhibitors of factor Xa (2001-04-03),
13. 6210913 - Modulation of integrin-mediated signal transduction (2001-04-03),
14. 6204268 - Selective factor Xa inhibitors (2001-03-20),
15. 6197748 - Ketoheterocyclic inhibitors of factor Xa (2001-03-06),
Company Overview
Cor Therapeutics, Inc., based in South San Francisco, CA, specializes in the development of innovative therapies targeting cardiovascular diseases. The company focuses on Factor Xa inhibitors, which play a crucial role in anticoagulation therapy, and explores related technologies such as thrombin receptor modulation and platelet aggregation inhibition. Cor Therapeutics is dedicated to advancing treatment options through its expertise in benzamides, ketoheterocyclic compounds, and integrin pathways, aiming to improve patient outcomes in the cardiovascular domain.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

92 Patents

#15 in South San Francisco, CA

#954 in California

#4,083 in US

#8,392 in the World

South San Francisco, CA (US)
South San Francisco, CA, United States of America

Cor Therapeutics, Inc.

Forward Citations = 914

41 inventors:

goldMedal Robert M Scarborough (59 out of 153 patents)

silverMedal David Lawrence Wolf (31 out of 33 patents)

bronzeMedal Bing-Yan Zhu (20 out of 79 patents)

4.  Israel F Charo (20 out of 23 patents)

5.  Uma Sinha (10 out of 32 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Cor Therapeutics, Inc.. Retrieved from https://idiyas.com/company/cor-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…